生物製藥產業市場－全球產業規模、佔有率、趨勢、機會及預測（按產品類型、治療應用、地區及競爭情況分類，2020-2030 年）

2024 年全球生物製藥產業市場價值為 4,358.2 億美元，預計在預測期內將實現顯著成長，到 2030 年的複合年成長率為 8.25%。全球生物製藥產業市場是更廣泛的製藥和醫療保健產業中一個充滿活力且快速發展的產業。它涵蓋生物製藥產品的開發、生產和商業化，這些產品是源自生物來源（例如生物體、細胞或蛋白質）的藥物和療法。這些產品代表了醫療保健領域的重大進步，為多種疾病和醫療狀況提供高度針對性和有效的治療。

全球生物製藥市場多年來一直保持穩定的成長軌跡。這一成長是由全球人口老化、慢性病發病率上升、醫療保健支出增加以及創新生物製藥產品的不斷推出等因素所推動的。即使在經濟低迷時期，市場也表現出了韌性，這對製藥公司和投資者來說是一個有吸引力的投資機會。

主要市場促進因素

研發創新

主要市場挑戰

監管障礙和合規複雜性

主要市場趨勢

生物技術進步與個人化醫療

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球生物製藥產業市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依產品類型（單株抗體、重組生長因子、純化蛋白質、重組蛋白質、重組激素、疫苗、重組酶、細胞和基因療法、合成免疫調節劑、其他）
  • 依治療應用（腫瘤學、發炎和感染性疾病、自體免疫疾病、代謝性疾病、荷爾蒙失調、心血管疾病、神經系統疾病、其他）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第6章：北美生物製藥產業市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 加拿大
  • 墨西哥

第7章：歐洲生物製藥產業市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 英國
  • 義大利
  • 法國
  • 西班牙

第8章：亞太生物製藥產業市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：南美洲生物製藥產業市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲生物製藥產業市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 最新動態
• 產品發布
• 合併與收購

第 13 章：全球生物製藥產業市場：SWOT 分析

第 14 章：競爭格局

• Abbvie Inc.
• Amgen Inc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Johnson & Johnson
• Novartis AG
• Novo Nordisk AS
• Pfizer Inc.
• GlaxoSmithKline PLC
• F. Hoffmann-La Roche AG

第 15 章：策略建議

第16章調查會社について,免責事項

Global Biopharmaceutical Industry Market was valued at USD 435.82 billion in 2024 and is anticipated to project significant growth in the forecast period with a CAGR of 8.25% through 2030. The Global Biopharmaceutical Industry Market is a dynamic and rapidly evolving sector within the broader pharmaceutical and healthcare industry. It encompasses the development, production, and commercialization of biopharmaceutical products, which are medicinal drugs and therapies derived from biological sources such as living organisms, cells, or proteins. These products represent a significant advancement in healthcare, offering highly targeted and effective treatments for a wide range of diseases and medical conditions.

The global biopharmaceutical market has been on a consistent growth trajectory for several years. This growth is driven by factors such as an aging global population, increasing prevalence of chronic diseases, rising healthcare expenditures, and the continuous introduction of innovative biopharmaceutical products. The market has demonstrated resilience even in the face of economic downturns, making it an attractive investment opportunity for pharmaceutical companies and investors.

Key Market Drivers

Research and Development Innovations

Research and development (R&D) innovations are at the heart of the biopharmaceutical industry. They are essential for the creation of novel therapies, drugs, and treatments. The importance of R&D innovations can be attributed to several factors. For instance, in February 2025, Zydus Lifesciences launched VaxiFlu-4, India's first quadrivalent influenza vaccine, representing a major advancement in vaccine technology. Developed at Zydus's Vaccine Technology Centre in Ahmedabad, it is formulated based on WHO recommendations to protect against emerging influenza virus strains.

With technological breakthroughs such as CRISPR-Cas9 gene editing, next-generation sequencing, and artificial intelligence, scientists can delve deeper into the understanding of diseases and develop innovative solutions. R&D innovations enable biopharmaceutical companies to tackle previously untreatable diseases and medical conditions, addressing unmet healthcare needs. Companies that invest heavily in R&D gain a competitive edge by bringing groundbreaking therapies to market, which can lead to substantial profits and market dominance. Continuous R&D ensures a pipeline of new drugs and therapies, fostering long-term sustainability for the biopharmaceutical industry.

Key Market Challenges

Regulatory Hurdles and Compliance Complexity

The biopharmaceutical industry operates in a highly regulated environment due to the critical nature of healthcare products. Regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), impose rigorous standards and requirements on the development, testing, and manufacturing of biopharmaceutical products. Meeting these regulatory standards can be a time-consuming and costly process. Companies must invest substantial resources in conducting clinical trials, documenting safety and efficacy data, and ensuring compliance with evolving regulations. Moreover, the variability in regulatory requirements across different countries and regions can pose a significant challenge for global market expansion. Additionally, as biopharmaceutical research advances into newer areas such as gene therapies and cell-based treatments, regulators are often grappling with the development of appropriate guidelines, which can further slowdown product approvals.

Key Market Trends

Biotechnology Advancements and Personalized Medicine

One of the most significant trends in the biopharmaceutical industry is the rapid advancement of biotechnology, particularly in areas like genomics, proteomics, and bioinformatics. These advancements are enabling the development of highly targeted and personalized medicines. Rather than taking a one-size-fits-all approach, biopharmaceutical companies are increasingly tailoring treatments to individual patients based on their genetic makeup, biomarkers, and specific disease characteristics. This trend is transforming the treatment landscape, allowing for more effective therapies with fewer side effects. Personalized medicine not only improves patient outcomes but also reduces healthcare costs by minimizing ineffective treatments and adverse reactions. Biopharmaceutical companies are investing heavily in research to identify biomarkers, develop companion diagnostics, and create therapies that precisely match a patient's genetic profile.

Key Market Players

• Abbvie Inc.
• Amgen Inc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Johnson & Johnson
• Novartis AG
• Novo Nordisk AS
• Pfizer Inc.
• GlaxoSmithKline PLC
• F. Hoffmann-La Roche AG

Report Scope:

In this report, the Global Biopharmaceutical Industry Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Biopharmaceutical Industry Market, By Product Type:

• Monoclonal Antibodies
• Recombinant Growth Factors
• Purified Proteins
• Recombinant Proteins
• Recombinant Hormones
• Vaccines
• Recombinant Enzymes
• Cell and Gene Therapies
• Synthetic Immunomodulators
• Others

Biopharmaceutical Industry Market, By Therapeutic Application:

• Oncology
• Inflammatory and Infectious Diseases
• Autoimmune Disorders
• Metabolic Disorders
• Hormonal Disorders
• Cardiovascular Diseases
• Neurological Diseases
• Other

Biopharmaceutical Industry Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Biopharmaceutical Industry Market.

Available Customizations:

Global Biopharmaceutical Industry market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Biopharmaceutical Industry Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Monoclonal Antibodies, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Vaccines, Recombinant Enzymes, Cell and Gene Therapies, Synthetic Immunomodulators, Others)
  • 5.2.2. By Therapeutic Application (Oncology, Inflammatory and Infectious Diseases, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders, Cardiovascular Diseases, Neurological Diseases, Other)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Biopharmaceutical Industry Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Therapeutic Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Biopharmaceutical Industry Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Therapeutic Application
  • 6.3.2. Canada Biopharmaceutical Industry Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Therapeutic Application
  • 6.3.3. Mexico Biopharmaceutical Industry Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Therapeutic Application

7. Europe Biopharmaceutical Industry Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Therapeutic Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Biopharmaceutical Industry Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Therapeutic Application
  • 7.3.2. United Kingdom Biopharmaceutical Industry Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Therapeutic Application
  • 7.3.3. Italy Biopharmaceutical Industry Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Therapeutic Application
  • 7.3.4. France Biopharmaceutical Industry Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Therapeutic Application
  • 7.3.5. Spain Biopharmaceutical Industry Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Therapeutic Application

8. Asia-Pacific Biopharmaceutical Industry Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Therapeutic Application
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Biopharmaceutical Industry Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Therapeutic Application
  • 8.3.2. India Biopharmaceutical Industry Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Therapeutic Application
  • 8.3.3. Japan Biopharmaceutical Industry Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Therapeutic Application
  • 8.3.4. South Korea Biopharmaceutical Industry Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Therapeutic Application
  • 8.3.5. Australia Biopharmaceutical Industry Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Therapeutic Application

9. South America Biopharmaceutical Industry Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Therapeutic Application
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Biopharmaceutical Industry Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Therapeutic Application
  • 9.3.2. Argentina Biopharmaceutical Industry Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Therapeutic Application
  • 9.3.3. Colombia Biopharmaceutical Industry Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Therapeutic Application

10. Middle East and Africa Biopharmaceutical Industry Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Therapeutic Application
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Biopharmaceutical Industry Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Therapeutic Application
  • 10.3.2. Saudi Arabia Biopharmaceutical Industry Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Therapeutic Application
  • 10.3.3. UAE Biopharmaceutical Industry Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Therapeutic Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Biopharmaceutical Industry Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Abbvie Inc.
• 14.2. Amgen Inc.
• 14.3. Bristol-Myers Squibb Company
• 14.4. Eli Lilly and Company
• 14.5. Johnson & Johnson
• 14.6. Novartis AG
• 14.7. Novo Nordisk AS
• 14.8. Pfizer Inc.
• 14.9. GlaxoSmithKline PLC
• 14.10. F. Hoffmann-La Roche AG

15. Strategic Recommendations

16. About Us & Disclaimer